| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_366a0ce26461e9c0375d766b208de8ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23a4e0c875bf1ac2b8a3b76517de6c7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_375c209c5bcef8f7a89c1b83c1757d71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21f87bc98a9147371689ca56989a3330
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c416e3a94fc271768afc718762f2dc08 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6913
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1278 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2011-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_057ed033a52a8b06d2dd7cba59406273
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ad8a69464d72a12f9d3c9a497d74c75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03c8af7da9c246fbd6beddd1a3b5c46a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7b7048160b71b0cec52cd2846169bd3 |
| publicationDate |
2012-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012065044-A2 |
| titleOfInvention |
Treating bladder tumor cells using fibronectin attachment protein as a target |
| abstract |
Composition and methods are disclosed for utilizing micro-aggregation of FAP- containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum- free conditions such as the ones found in the lumen of the bladder. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11007355-B2 |
| priorityDate |
2010-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |